Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial

Harry Erba • 7 Sep 2023
SOHO 2023
Acute Myeloid Leukemia Leukemia Midostaurin Quizartinib
QuANTUM-First

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the role of quizartinib in the treatment of patients with FLT3-ITD-mutated acute myeloid leukemia (AML), highlighting the results of the QuANTUM-First trial (NCT02668653). Dr Erba comments on the deeper responses and reduced risk of mortality observed with quizartinib compared to placebo, and recommends quizartinib as a frontline treatment in combination with intensive chemotherapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Harry Erba

MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays
7:48
MRD as a surrogate endpoint in AML: challenges, ongoing studies, and the need to standardize assays
Harry Erba • 28 Feb 2026
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
The Phase III QuANTUM-Wild trial: quizartinib in newly diagnosed FLT3-ITD-negative AML
6:43
The Phase III QuANTUM-Wild trial: quizartinib in newly diagnosed FLT3-ITD-negative AML
Harry Erba • 12 Jun 2025
Updated results of KOMET-007: exploring ziftomenib with 7+3 in newly diagnosed NPM1m or KMT2Ar AML
6:33
Updated results of KOMET-007: exploring ziftomenib with 7+3 in newly diagnosed NPM1m or KMT2Ar AML
Harry Erba • 12 Jun 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals